Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
GHRS 
GH Research PLC (GHRS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/09/2025: GHRS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $30.38
1 Year Target Price $30.38
| 5 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 51.65% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 907.49M USD | Price to earnings Ratio - | 1Y Target Price 30.38 |
Price to earnings Ratio - | 1Y Target Price 30.38 | ||
Volume (30-day avg) 8 | Beta 0.97 | 52 Weeks Range 6.72 - 20.50 | Updated Date 12/9/2025 |
52 Weeks Range 6.72 - 20.50 | Updated Date 12/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.73 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -14.18% | Return on Equity (TTM) -17.86% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 635692691 | Price to Sales(TTM) - |
Enterprise Value 635692691 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -11.97 | Shares Outstanding 62029395 | Shares Floating 23346624 |
Shares Outstanding 62029395 | Shares Floating 23346624 | ||
Percent Insiders 26.78 | Percent Institutions 71.97 |
Upturn AI SWOT
GH Research PLC
Company Overview
History and Background
GH Research PLC is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for a range of diseases. Founded in 2019, its primary focus has been on the exploration of psychedelic compounds for mental health conditions.
Core Business Areas
- Psychedelic Therapeutics Development: GH Research PLC is dedicated to the research, development, and potential commercialization of novel psychedelic-based medicines. Their core activity involves clinical trials and drug discovery, aiming to address unmet medical needs in psychiatry.
Leadership and Structure
GH Research PLC is led by a management team with expertise in biotechnology and clinical development. The company operates under a typical corporate structure with a board of directors overseeing its strategic direction and executive management responsible for day-to-day operations.
Top Products and Market Share
Key Offerings
- GH001 (Ketamine Hydrochloride): GH001 is a novel formulation of ketamine hydrochloride for the treatment of depression. It is currently undergoing clinical trials. Competitors in the broader depression treatment market include established pharmaceutical companies with a wide range of antidepressant medications. In the emerging psychedelic therapy space, competitors include companies exploring psilocybin, MDMA, and other novel compounds.
- GH002 (Psilocybin): GH002 is being investigated for the treatment of various psychiatric disorders. Similar to GH001, it faces competition from established pharmaceutical companies and emerging players in the psychedelic therapeutic space.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the segment focused on central nervous system (CNS) disorders and mental health, is a rapidly evolving field. There is a growing recognition of unmet needs in treating conditions like depression, PTSD, and addiction, leading to increased investment in novel therapeutic approaches, including psychedelic-assisted therapies.
Positioning
GH Research PLC is positioned as an emerging player in the psychedelic therapeutics market. Its competitive advantage lies in its focus on novel formulations and proprietary delivery methods, as well as its commitment to rigorous clinical development pathways. However, as a clinical-stage company, it faces significant risks associated with drug development and regulatory approval.
Total Addressable Market (TAM)
The TAM for mental health therapeutics is substantial, with the global depression market alone valued in the tens of billions of dollars. The emerging psychedelic therapy market, while smaller, is projected for significant growth. GH Research PLC is targeting specific segments within this TAM, with the potential for high revenue if their lead candidates achieve regulatory approval and market penetration.
Upturn SWOT Analysis
Strengths
- Focus on a high-growth, underserved market segment (psychedelic therapeutics).
- Proprietary formulation and delivery system for novel compounds.
- Experienced management team with clinical development expertise.
- Potential for significant therapeutic impact on difficult-to-treat conditions.
Weaknesses
- Clinical-stage company with no approved products.
- High financial burn rate due to extensive R&D and clinical trials.
- Reliance on successful outcomes of ongoing clinical trials.
- Regulatory uncertainty surrounding psychedelic substances.
- Limited historical financial data and operational history.
Opportunities
- Growing acceptance and de-stigmatization of psychedelic therapies.
- Advancements in clinical trial methodologies and patient recruitment.
- Potential for partnerships with larger pharmaceutical companies.
- Expansion into other indications beyond depression.
- Emerging global market for mental health treatments.
Threats
- Failure of clinical trials to meet efficacy or safety endpoints.
- Stricter regulatory hurdles or changes in drug scheduling.
- Intensifying competition from other psychedelic therapy developers.
- Challenges in scaling manufacturing and distribution.
- Negative public perception or unexpected adverse events in the broader psychedelic research field.
Competitors and Market Share
Key Competitors
- MindMed Inc. (MNMD)
- Compass Pathways PLC (CMPS)
- Cybin Inc. (CYBN)
Competitive Landscape
GH Research PLC competes in a rapidly emerging and highly competitive landscape. While it has a focused strategy and potential for differentiated formulations, it faces competition from companies with established clinical pipelines, diversified research platforms, and greater financial resources. The key to success lies in demonstrating superior efficacy, safety, and a clear path to regulatory approval compared to its peers.
Growth Trajectory and Initiatives
Historical Growth: GH Research PLC is in its early stages of growth, with its history primarily defined by its founding and progression through early-stage research and preclinical development. Its growth is measured by milestones such as successful IND submissions and initiation of clinical trials.
Future Projections: Future projections are highly dependent on the success of its clinical pipeline, particularly GH001 and GH002. Analyst projections, if available, would likely focus on the potential market size and revenue upon successful commercialization, balanced against significant development risks.
Recent Initiatives: Recent initiatives would include ongoing patient enrollment in clinical trials, manufacturing process development, and engagement with regulatory bodies. Strategic partnerships or licensing agreements could also be considered initiatives.
Summary
GH Research PLC is an early-stage biopharmaceutical company focused on developing novel psychedelic-based therapies. Its strengths lie in its targeted approach to a growing market and potential for breakthrough treatments. However, it faces significant weaknesses due to its pre-commercial status, high R&D costs, and regulatory uncertainties. The company must navigate intense competition and demonstrate robust clinical efficacy to achieve its growth potential.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company investor relations websites
- SEC filings (10-K, 10-Q)
- Financial news outlets
- Industry research reports
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. The information provided is based on publicly available data and estimations. Investors should conduct their own due diligence before making any investment decisions. Market share data and TAM figures are estimates and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GH Research PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-06-25 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 50 | Website https://www.ghres.com |
Full time employees 50 | Website https://www.ghres.com | ||
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.